PRCT: הכנסות ממכירות החברה PROCEPT BioRobotics Corporation

PROCEPT BioRobotics (PRCT) sales volume history confirms its dominance in the aquablation segment, driven by patents and FDA approval. Efficiency is hampered by a reliance on contract assembly and cloud services, although geopolitical neutrality minimizes supply chain disruptions. The current value of 0.35 reflects this status, helping investors assess real cash flow and avoid overpaying for the asset.

PROCEPT BioRobotics (PRCT) sales reflect the aggregate cash inflow from core operations, allowing investors to assess the business's resilience to market shocks and mitigate risks in a timely manner. An analysis of the company's product sales confirms the effectiveness of the AquaBeam model, where revenue growth depends directly on the expansion of the robot fleet and steady demand for ancillary consumables.